{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:52:20Z","timestamp":1794552740095,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trim.2025.102312","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:46:54Z","timestamp":1760071614000},"page":"102312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Transplant outcomes after de novo donor specific antibody (DSA) development correlate with persistence of DSA"],"prefix":"10.1016","volume":"93","author":[{"given":"A.","family":"Jaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_7","key":"10.1016\/j.trim.2025.102312_bb0005","first-page":"vii138","article-title":"Measures of care in adult renal transplant recipients in the United Kingdom (chapter 11)","volume":"22","author":"Ravanan","year":"2007","journal-title":"Nephrol. Dialysis Transplantat."},{"key":"10.1016\/j.trim.2025.102312_bb0010","first-page":"56","article-title":"Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial","author":"Stringer","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.trim.2025.102312_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am. J. Transplant."},{"issue":"6","key":"10.1016\/j.trim.2025.102312_bb0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.humimm.2018.02.014","article-title":"Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes","volume":"79","author":"Redondo-Pach\u00f3n","year":"2018","journal-title":"Hum. Immunol."},{"issue":"4","key":"10.1016\/j.trim.2025.102312_bb0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0b013e3181b11b72","article-title":"HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss","volume":"88","author":"Lee","year":"2009","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.trim.2025.102312_bb0030","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/01.tp.0000174338.97313.5a","article-title":"Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial","volume":"80","author":"Terasaki","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.trim.2025.102312_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2025.102312_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3343\/alm.2023.43.4.364","article-title":"Impact of low-level donor-specific anti-HLA antibody on posttransplant clinical outcomes in kidney transplant recipients","volume":"43","author":"Lee","year":"2023","journal-title":"Ann. Lab. Med."},{"issue":"4","key":"10.1016\/j.trim.2025.102312_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.humimm.2021.02.004","article-title":"Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?","volume":"82","author":"Wen","year":"2021","journal-title":"Hum. Immunol."},{"issue":"10","key":"10.1016\/j.trim.2025.102312_bb0050","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/jcm12103361","article-title":"Impact of resolved preformed, persistent preformed, and De novo anti-HLA donor-specific antibodies in kidney transplant recipients on long-term renal graft outcomes","volume":"12","author":"Gniewkiewicz","year":"2023","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.trim.2025.102312_bb0055","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/ajt.15414","article-title":"Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation","volume":"19","author":"Senev","year":"2019","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2025.102312_bb0060","doi-asserted-by":"crossref","first-page":"21538","DOI":"10.1038\/s41598-025-07681-4","article-title":"Persistent versus resolved donor-specific antibodies predict 10-year antibody-mediated rejection and kidney transplant outcomes in Thailand","volume":"15","author":"Thammathiwat","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.trim.2025.102312_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/0886022X.2014.991997","article-title":"Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients","volume":"37","author":"Tian","year":"2015","journal-title":"Ren. Fail."},{"issue":"8","key":"10.1016\/j.trim.2025.102312_bb0070","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.trim.2025.102312_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOT.0000000000000593","article-title":"Measuring alloantibodies: a matter of quantity and quality","volume":"24","author":"Kiernan","year":"2019","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"13","key":"10.1016\/j.trim.2025.102312_bb0080","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.3390\/jcm12134475","article-title":"Clinical outcome of kidney transplant recipients with C1q-binding De novo donor specific antibodies: a single-Center experience","volume":"12","author":"Marinaki","year":"2023","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.trim.2025.102312_bb0085","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.transproceed.2020.06.022","article-title":"Mid-term outcomes after treatment for antibody-mediated rejection by De novo donor-specific HLA antibody in renal transplant recipients: does early treatment Lead to better outcomes?","volume":"52","author":"Okada","year":"2020","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2025.102312_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.943502","article-title":"The natural history of de novo donor-specific HLA antibodies after kidney transplantation","volume":"9","author":"L\u00f3pez del Moral","year":"2022","journal-title":"Front. Med."},{"issue":"10","key":"10.1016\/j.trim.2025.102312_bb0095","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Anti-human leukocyte antigen and donor-specific antibodies detected by lunex posttransplant serve as biomarkers for chronic rejection of renal allografts","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.trim.2025.102312_bb0100","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am. J. Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425001406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425001406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:14:09Z","timestamp":1765055649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327425001406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"alternative-id":["S0966327425001406"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102312","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplant outcomes after de novo donor specific antibody (DSA) development correlate with persistence of DSA","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102312"}}